Medicamen Biotech Share Price Today | Stock Price & Medicamen Biotech Share Screener
As of September 16, 2026, the live Medicamen Biotech share price (NSE: MEDICAMEQ) is ₹345.50 on NSE and ₹308.75 on BSE, up 8.58% from the previous close, with shares trading between ₹290.55 and ₹354.40 in today's trading session, and a 52-week range of ₹219.88–₹415.95. Check MEDICAMEQ 52-week chart for the annual price range and momentum. Use the Medicamen Biotech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Medicamen Biotech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹62 and net income of ₹4, with EBITDA of ₹7, an operating margin of 9.0% and a profit margin of 6.5%.
Medicamen Biotech Share Price Chart
Track the current stock price of Medicamen Biotech with an interactive chart. Analyse MEDICAMEQ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Medicamen Biotech stock quote in one place.
The quote of ₹345.50 sits between the 52-week low of ₹219.88 and the 52-week high of ₹415.95, and the latest session moved 8.58% from the previous close.
Medicamen Biotech Company Profile - Fundamental Screener
Screen Medicamen Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MEDICAMEQ shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE646B01010.
Company Details
Classification
Identifiers and Leadership
Medicamen Biotech Balance Sheet Screener
Screen MEDICAMEQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹372, up from ₹297 in 2025.
Latest statistics put total assets at ₹372 and shareholder funds at ₹276, with a leverage ratio of 0.17.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 372 | 297 | 295 | 279 | 226 | 194 | 181 | 137 |
| Current Assets | 224 | 165 | 160 | 163 | 123 | 96 | 104 | 96 |
| Fixed Assets | 85 | 87 | 92 | 93 | 93 | 90 | 34 | 24 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 9 | 6 | 3 | 3 | 7 | 8 | 4 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 276 | 213 | 207 | 193 | 147 | 133 | 121 | 87 |
| Share Capital | 14 | 13 | 13 | 13 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | 253 | 200 | 194 | 178 | 134 | 121 | 109 | 75 |
Medicamen Biotech Income Statement Screener - Profit & Revenue Analysis
Screen Medicamen Biotech income statement and profit fundamentals. Analyze MEDICAMEQ quarterly results. Medicamen Biotech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹62 and net profit was ₹4, equal to earnings per unit of ₹3.28, at an operating margin of 9%.
In that period expenses were ₹55, interest cost ₹0 and tax ₹1. The next period listed, 2026-Jun, shows revenue of ₹49 and net profit of ₹2.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 62 | 49 | 35 | 44 | 48 | 47 | 48 | 44 | 45 | 45 | 39 | 42 | 44 | 47 | 23 |
| Expenses | 55 | 44 | 31 | 38 | 42 | 43 | 42 | 40 | 39 | 38 | 32 | 35 | 39 | 42 | 18 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 7 | 5 | 4 | 5 | 6 | 5 | 6 | 4 | 6 | 7 | 7 | 7 | 5 | 6 | 5 |
| Operating Profit % | 9.00% | 9.00% | -5.00% | 11.00% | 11.00% | 9.00% | 12.00% | 8.00% | 12.00% | 15.00% | 17.00% | 17.00% | 11.00% | 11.00% | 22.00% |
| Depreciation | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 5 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 4 | 4 | 5 | 3 | 3 | 3 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Profit | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 3 | 4 | 4 | 2 | 2 | 3 |
| EPS | 3.28 | 1.36 | 1.47 | 1.18 | 1.56 | 1.21 | 1.61 | 0.63 | 0.71 | 2.30 | 3.03 | 3.12 | 1.17 | 1.60 | 2.25 |
Medicamen Biotech Cash Flow Screener - Liquidity Fundamentals
Screen MEDICAMEQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹33, and net cash flow was an inflow of ₹28.
Over the same period, investing activities used ₹3 and financing activities provided ₹64.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||
| Operating Activities | -33 | -8 | -7 | -6 | 4 | 13 | 13 | 4 |
| Investing Activities | -3 | -1 | -6 | -6 | -9 | -18 | -37 | -15 |
Financing and Net Cash | ||||||||
| Financing Activities | 64 | -2 | 6 | 29 | 4 | 6 | 19 | -4 |
| Net Cash Flow | 28 | -11 | -6 | 17 | 0 | 1 | -5 | -14 |
Medicamen Biotech Shareholding Pattern Screener
See Medicamen Biotech shareholding pattern with promoter, FII, and DII holdings. Check Medicamen Biotech promoter holding and ownership changes for MEDICAMEQ on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 40.46%, foreign institutions 0.10%, domestic institutions 0.00% and the public 32.09%, spread across 10,806 shareholders.
The shareholder count was 10,806 in 2026-Mar, compared with 11,047 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Apr | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 40.46% | 40.46% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 43.21% |
Institutional Investors | ||||||||
| FII Holding | 0.10% | 0.07% | 0.12% | 0.22% | 0.00% | 0.06% | 0.02% | 0.11% |
| DII Holding | 0.00% | 0.40% | 0.69% | 0.65% | 0.64% | 0.59% | 0.44% | 0.99% |
Government, Public and Others | ||||||||
| Govt Holding | 0.05% | 0.05% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.00% |
| Public Holding | 32.09% | 32.10% | 33.35% | 31.58% | 31.50% | 33.35% | 32.17% | 31.95% |
| Other Holding | 27.30% | 26.91% | 22.63% | 27.04% | 27.34% | 25.50% | 26.86% | 23.74% |
| Shareholder Count | 10,806 | 11,047 | 10,435 | 10,592 | 10,808 | 11,177 | 10,967 | 10,639 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Medicamen Biotech. Medicamen Biotech dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹1.00 per unit for 2026-March, a yield of 0.31%, compared with ₹1.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹1.00, ₹1.00 and ₹1.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹1.00 | 0.31% |
| 2025-March | ₹1.00 | 0.45% |
| 2024-March | ₹1.00 | 0.21% |
| 2023-March | ₹1.00 | 0.26% |
| 2022-March | ₹1.00 | 0.15% |
| 2021-March | ₹1.00 | 0.16% |
| 2020-March | ₹0.50 | 0.09% |
| 2019-March | ₹1.00 | 0.55% |
| 2018-March | ₹1.00 | 0.21% |
| 2017-March | ₹0.00 | 0.00% |
Medicamen Biotech Stock Index Membership - Nifty & Sensex
See which indices include Medicamen Biotech stock. Check MEDICAMEQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Medicamen Biotech Market Events Screener - Corporate Actions
Get Medicamen Biotech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Medicamen Biotech stock events that may affect MEDICAMEQ share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 26, 2026, with a record date of September 26, 2026.
It is followed by Dividend dated September 18, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-26 | 2026-09-26 | Annual General Meeting | NA | 30.97% |
| 2026-09-18 | 2026-09-19 | Dividend | ₹ 1.00 /share | 21.73% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 0.89% |
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 0.78% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -6.83% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 7.40% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -9.63% |
| 2025-09-19 | 2025-09-19 | Dividend | ₹ 1.00 /share | -22.18% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -4.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.82% |
| 2025-03-26 | 2025-03-26 | Extraordinary General Meeting | NA | -16.66% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 6.85% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -14.31% |
| 2024-09-26 | 2024-09-26 | Annual General Meeting | NA | 20.69% |
| 2024-09-19 | 2024-09-19 | Dividend | ₹ 1.00 /share | -10.33% |
Medicamen Biotech Competitors Screener - Peer Stocks Comparison
Screen MEDICAMEQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,394 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 243,368 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 180,458 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 113,965 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,011 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 106,182 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 102,551 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,304 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,180 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 91,988 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Medicamen Biotech Company Announcements - News & Reports Screener
Screen MEDICAMEQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 29, 2026 and September 28, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations 2015 | - |
| 2026-09-29 | Voting Reults Of 33Rd Annual General Meeting - September 26 2026 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-27 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-03 | Reg. 34 (1) Annual Report. | - |
| 2026-09-03 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-09-03 | Annual Report 2025-26 | - |
| 2026-09-03 | Notice Of 33Rd Annual General Meeting - September 26 2026 | - |
| 2026-08-18 | Intimation Of Book Clsoure And Record Date In Accordance With Regulation 42 Of The SEBI (Listing Obligationa And Disclosure Requirements) Regulation 2015 | - |
| 2026-08-17 | Corpoarte Action - Fixes Record Date As September 19 2026 For The Purpose Of Declaration Of Final Dividend For The FY 2025-26. | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Closure Of Register Of Members And Share Transfer Books | - |
| 2026-08-14 | Financial Results For The Quarter Ended On June 30 2026. | - |
| 2026-08-07 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter Ended 30 June 2026. | - |
| 2026-07-28 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-28 | Corporate Action-Board to consider Dividend | - |
| 2026-05-28 | Compliances - Regulation 32 (1) And (3) - Statament Of Deviation & Variation Report - March 2026 | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹345.50, within a 52-week range of ₹219.88 to ₹415.95. The P/E ratio is 42.61 and the P/B ratio is 1.60, with earnings per unit of ₹7.22. Market capitalisation stands at ₹419.09 Cr and the dividend yield is 0.32%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.